A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Registry ID

HQP1351CU101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ASCENTAGE PHARMA GROUP INC.

Start date

2024-01-08

Last update

2022-06-17

Conditions

• CHRONIC MYELOID LEUKEMIA
• ACUTE LYMPHOBLASTIC LEUKEMIA

Related clinical trials

• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
• A MODULAR PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF AZD4512 MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
• RE-TREATMENT WITH SECOND GENERATION, ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ACIT001-3)
• A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
• A PHASE 1A/1B STUDY OF ELVN-001 FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
• A RANDOMIZED TRIAL OF LEVOCARNITINE PROPHYLAXIS TO PREVENT ASPARAGINASE-ASSOCIATED HEPATOTOXICITY IN ADOLESCENTS AND YOUNG ADULTS RECEIVING ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY

View on source registry